Adam Walsh
Stock Analyst at Roth MKM
(3.52)
# 2,266
Out of 5,004 analysts
141
Total ratings
40.9%
Success rate
5.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Adam Walsh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARCT Arcturus Therapeutics Holdings | Reiterated: Buy | $41 | $13.85 | +196.03% | 10 | Sep 24, 2026 | |
| OSTX OS Therapies | Reiterated: Buy | $7 | $1.66 | +321.69% | 5 | Sep 22, 2026 | |
| INSM Insmed | Reiterated: Buy | $212 → $198 | $117.83 | +68.04% | 23 | Sep 15, 2026 | |
| BIOA BioAge Labs | Reiterated: Buy | $25 | $7.05 | +254.61% | 5 | Sep 9, 2026 | |
| EQ Equillium | Reiterated: Buy | $12 | $1.67 | +618.56% | 12 | Sep 4, 2026 | |
| VTVT vTv Therapeutics | Reiterated: Buy | $58 | $30.21 | +91.99% | 6 | Aug 7, 2026 | |
| RARE Ultragenyx Pharmaceutical | Reiterated: Buy | $70 → $82 | $14.50 | n/a | 19 | May 18, 2020 | |
| ASND Ascendis Pharma | Reiterated: Buy | $81 → $171 | $225.60 | n/a | 3 | Apr 20, 2020 | |
| LKFT Lakefront Biotherapeutics NV | Reiterated: Buy | $298 | $29.38 | n/a | 9 | Apr 8, 2020 | |
| CORT Corcept Therapeutics | Reiterated: Hold | n/a | $116.10 | n/a | 8 | Feb 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $71 | $6.94 | n/a | 2 | Nov 12, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $36 → $25 | $1.21 | n/a | 4 | Jun 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $11 → $17 | $141.86 | n/a | 3 | May 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $129 → $182 | $526.19 | n/a | 13 | Jul 18, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $105 → $107 | $60.26 | n/a | 5 | Mar 3, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $221.37 | $8.06 | n/a | 1 | Nov 30, 2015 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $160 | $255.96 | n/a | 11 | Jun 24, 2015 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $16 → $30 | $18.67 | n/a | 2 | May 20, 2015 |
Arcturus Therapeutics Holdings
Sep 24, 2026
Reiterated: Buy
Price Target: $41
Current: $13.85
Upside: +196.03%
OS Therapies
Sep 22, 2026
Reiterated: Buy
Price Target: $7
Current: $1.66
Upside: +321.69%
Insmed
Sep 15, 2026
Reiterated: Buy
Price Target: $212 → $198
Current: $117.83
Upside: +68.04%
BioAge Labs
Sep 9, 2026
Reiterated: Buy
Price Target: $25
Current: $7.05
Upside: +254.61%
Equillium
Sep 4, 2026
Reiterated: Buy
Price Target: $12
Current: $1.67
Upside: +618.56%
vTv Therapeutics
Aug 7, 2026
Reiterated: Buy
Price Target: $58
Current: $30.21
Upside: +91.99%
Ultragenyx Pharmaceutical
May 18, 2020
Reiterated: Buy
Price Target: $70 → $82
Current: $14.50
Upside: n/a
Ascendis Pharma
Apr 20, 2020
Reiterated: Buy
Price Target: $81 → $171
Current: $225.60
Upside: n/a
Lakefront Biotherapeutics NV
Apr 8, 2020
Reiterated: Buy
Price Target: $298
Current: $29.38
Upside: n/a
Corcept Therapeutics
Feb 10, 2020
Reiterated: Hold
Price Target: n/a
Current: $116.10
Upside: n/a
Nov 12, 2019
Reiterated: Buy
Price Target: $71
Current: $6.94
Upside: n/a
Jun 25, 2019
Reiterated: Buy
Price Target: $36 → $25
Current: $1.21
Upside: n/a
May 8, 2019
Upgraded: Buy
Price Target: $11 → $17
Current: $141.86
Upside: n/a
Jul 18, 2017
Rated: Buy
Price Target: $129 → $182
Current: $526.19
Upside: n/a
Mar 3, 2016
Reiterated: Buy
Price Target: $105 → $107
Current: $60.26
Upside: n/a
Nov 30, 2015
Initiated Coverage: Buy
Price Target: $221.37
Current: $8.06
Upside: n/a
Jun 24, 2015
Reiterated: Buy
Price Target: $160
Current: $255.96
Upside: n/a
May 20, 2015
Upgraded: Buy
Price Target: $16 → $30
Current: $18.67
Upside: n/a